Click on image to view larger version.

Figure 1 Kaplan-Meier curves of 30-day composite of death, nonfatal myocardial infarction (MI), and urgent target vessel revascularization (TVR) in patients according to clopidogrel pretreatment and assignment of glycoprotein IIb/IIIa inhibitors. The clinical benefit of clopidogrel pretreatment was present regardless of which IIb/IIIa agent was used. Abciximab was superior to tirofiban in terms of 30-day composite end point; however, the extent appears attenuated in the presence of clopidogrel pretreatment.